SYS-CON MEDIA Authors: Elizabeth White, Doug Masi, Mat Mathews, PR.com Newswire, David Smith

News Feed Item

Quintiles Honored for IT Innovation, Named to 2014 CIO 100

Quintiles, the world’s largest biopharmaceutical services provider, has been named to the 2014 CIO 100. Each year, CIO magazine identifies and honors 100 organizations that have distinguished themselves by creating business value through the effective and innovative use of IT.

Richard Thomas, Quintiles CIO - "Infosario Safety helps conquer some of the complexity involved in s ...

Richard Thomas, Quintiles CIO - "Infosario Safety helps conquer some of the complexity involved in safeguarding patients. We believe technology innovation must be focused on success in human measures." (Photo: Business Wire)

Quintiles was named to the CIO 100 because of its transformational Quintiles Infosario® Safety solution, a drug safety technology platform which is fully integrated with relevant regulatory agencies and future-proofed through a community development model.

“We are honored to be included in the CIO 100 for our work in helping to solve industry and customer challenges,” said Quintiles CIO Richard Thomas. “Introduced in 2011, our award-winning Infosario solutions combine our deep scientific and operational expertise with industry-leading technology innovations that improve our customers’ probability of success at every step of the way.”

During development of Quintiles Infosario Safety, the company consolidated more than 35 individual drug safety systems and pooled a wide range of best practices and processes to create a highly optimized and efficient operating model to help its biopharmaceutical customers ensure that all regulatory requirements for drug safety management are met on a global basis. Quintiles then developed an entire portfolio of safety applications, regulatory agency integrations and implementation accelerators virtualized and deployed in its private cloud, securely available 24 hours a day, seven days a week via web browser.

This success led to the introduction of a platform that provides customers with benefits including, but not limited to:

  • Massive cost reductions versus legacy solutions;
  • Automated regulatory agency and partner integration;
  • Guaranteed information exchange;
  • Comprehensive safety capabilities and best-of-breed processes;
  • Enhanced regulatory and operational reporting capabilities;
  • Enhanced compliance;
  • Secure environment, guaranteeing patient privacy and pharma confidentiality.

“We take tremendous pride in this recognition, but what really drives us is our passion to help patients,” continued Thomas. “Patient safety is a top priority for us, just as it is for our customers. Infosario Safety helps conquer some of the complexity involved in safeguarding patients. We believe technology innovation must be focused on success in human measures.”

"For 27 years now, the CIO 100 awards have honored the innovative use of technology to deliver genuine business value," said Maryfran Johnson, editor in chief of CIO magazine and events. "Our 2014 winners are an outstanding example of the transformative power of IT to drive everything from revenue growth to competitive advantage."

About Quintiles

Quintiles (NYSE: Q) is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. We helped develop or commercialize all of 2013’s top-100 best-selling drugs on the market. Quintiles applies the breadth and depth of our service offerings along with extensive therapeutic, scientific and analytics expertise to help our customers navigate an increasingly complex healthcare environment as they seek to improve efficiency and effectiveness in the delivery of better healthcare outcomes. To learn more about Quintiles, please visit www.quintiles.com.

Click here to subscribe to Mobile Alerts for Quintiles.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.